Immune checkpoint inhibitors, such as PD-1 and its ligand, PD-L1, and CTLA-4, play an active role in the evasion of tumor surveillance and therapeutic resistance of MDS cells [21, 22]. The gene discussed is CTLA4; the disease is myelodysplastic syndrome.